{{Rsnum
|rsid=1833489
|Gene=CNTN5
|Chromosome=11
|position=100001440
|Orientation=plus
|GMAF=0.3287
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=CNTN5
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 9.8 | 39.3 | 50.9
| HCB | 1.5 | 19.0 | 79.6
| JPT | 3.6 | 14.3 | 82.1
| YRI | 47.9 | 45.1 | 6.9
| ASW | 43.6 | 34.5 | 21.8
| CHB | 1.5 | 19.0 | 79.6
| CHD | 1.9 | 19.4 | 78.7
| GIH | 12.2 | 46.9 | 40.8
| LWK | 38.5 | 45.0 | 16.5
| MEX | 6.9 | 32.8 | 60.3
| MKK | 26.6 | 53.9 | 19.5
| TSI | 14.9 | 39.6 | 45.5
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs1833489
|Name_s=
|Gene_s=CNTN5
|Feature=
|Evidence=PubMed ID:17537913
|Annotation=Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 89. Study population/ethnicity: 89 Yorubans. Significance metric(s): p = 0.00005. Type of association: FA; GN.
|Drugs=etoposide
|Drug Classes=
|Diseases=Drug Toxicity
|Curation Level=Curated
|PharmGKB Accession ID=PA165109356
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs1833489
|overall_frequency_n=52
|overall_frequency_d=128
|overall_frequency=0.40625
|n_genomes=35
|n_genomes_annotated=0
|n_haplomes=47
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Illumina Human 1M}}